Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of glycan-trimmed HIV-1 nanoparticle vaccine UVAX-1107, followed by UVAX-1197 booster, with adjuvant, in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• UVAX-1107
• UVAX-1197

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1-infection | Phase 1 | Status: SUSPENDED